Halozyme just blocked Merck's injected Keytruda in Europe — ride the post-court-win momentum

Verdict: the court win is real, but the entry hasn't earned your money yet

The strongest case for this trade is the October 7, 2026 Reuters report that Halozyme won a court order blocking Merck's injected Keytruda in select European markets, which directly protects the royalty stream, and Halozyme's Q2 2026 quarter backs it up: revenue up 27.7% to $481.0M, net income up 53.2% to $229.9M, and operating margin up roughly 10.8 points to 59.8%. The strongest case against is that both entry legs are nowhere near triggered — HALO sits about 6.5% above its 50-day EMA at $103.93 with RSI at 51.0 versus the 45 threshold, and MRK about 7.3% above its EMA — and the provisional filings for the September 30, 2026 period show net insider open-market selling of roughly $18.8M at HALO and $28.6M at MRK, which is unfriendly for a thesis premised on insider-adjacent conviction. The 60-month backtest offers a realized read (19.0% return, 40% win rate, 16.4% max drawdown over 15 trades), but no robust nearby-parameter setup was established, so the published thresholds are what to watch. If insiders reverse to net buying in the next filing, or a hearing date clarifies the legal timeline, this flips from watch to act.

Trade now: HALO long is a pullback setup, and the pullback hasn't come yet

The idea argues HALO is the cleaner long side of the HALO/MRK pair around the Keytruda royalties dispute, and the completed backtest supports the framework: over 60 months on daily bars the HALO leg returned 19.0% across 15 trades with a 40% win rate and a 16.4% maximum drawdown. But the strategy does not buy the news — it waits for the post-ruling repricing to pull back, and right now it hasn't. HALO closed at $110.42 with RSI (14) at 51.0 and the price sitting roughly 6.5% above the 50-day EMA at $103.93. The entry needs price at or below the 50-day average and RSI to cross back above 45 from below; RSI is 6.0 points above that threshold, so the momentum condition is not there yet. The MACD-versus-signal cross is the only condition currently near its trigger. On the MRK side the picture is similar: the stock closed at $145.6, about 7.3% above its 50-day EMA of $138.3, with RSI at 54.2 — 9.2 points above the 45 threshold. Neither leg is close to a valid entry today, and chasing strength here would mean buying without the strategy's confirmation conditions in place. Risk and reward are defined by the exits. Once a position is open, the strategy takes profit at 4.6% (or at first resistance — $111.15 for HALO) and cuts losses at 2.3%, with a hard stop if price crosses below the second support level ($105.5 for HALO) and a 90-day holding cap. That works out to a reward-to-risk of roughly 2-to-1 on the fixed stop, and sizing is fixed-risk at 2.28% of equity per position with a 25% maximum allocation. What "wait" means concretely: do nothing until HALO trades back down to roughly the $104 area (at or below the 50-day EMA) with RSI having first dipped and then crossed back above 45, and MACD crossing above its signal — and the equivalent conditions on MRK. If the tape keeps running away from the 50-day average, the setup simply does not trigger, and the discipline is to let it. No robust nearby-parameter setup was established, so the published thresholds are what to watch.

A royalty stream the court just fenced off — and fundamentals that were already accelerating

The core thesis holds together on the demand side of the equation. Per the Reuters report of October 7, 2026, Halozyme won a court order blocking Merck's injected form of Keytruda in select European markets — and Halozyme's economics are built exactly on that stream: it collects royalties on the devices used with injected versions of Keytruda, so a legal barrier protecting the infusion route protects the fee base. The idea's point about binary catalysts is consistent with the event structure: a ruling is a step-change, not a drift, and the leg of the pair that benefits unambiguously is HALO on the long side. The standalone fundamentals give that legal tailwind something real to carry. In the quarter ended June 30, 2026, Halozyme grew revenue 27.7% quarter over quarter to $481.0M, lifted net income 53.2% to $229.9M, and expanded operating margin by roughly 10.8 points to 59.8% while gross margin improved to 83.5%. Free cash flow rose 34.2% to $236.7M, and shares outstanding fell 3.78% quarter over quarter — so growth arrived alongside per-share support rather than dilution. Even the trailing full-year 2025 snapshot shows a 51.6% year-over-year revenue increase and free cash flow of $217.6M, ranking in the 94.9th percentile among 1,020 health care peers. The MRK-side leg reinforces the trade design rather than undermining it. Merck grew revenue only 2.0% to $16.6B in the same quarter and posted a net loss of -$1.3B, versus -$4.2B the prior quarter — and with its biggest drug facing a legal route restriction, the thesis logic that MRK bears the pressure while HALO benefits makes HALO the cleaner long leg. Merck's latest full-year snapshot showed year-over-year revenue growth of just 5.0%, placing it at the 41.7th percentile for health care revenue growth, versus Halozyme's 79.0th percentile — the asymmetry between the two supports treating HALO, not MRK, as the primary…

Scores

• Conviction score breakdown: 52
• Thesis support: 80
• Trade readiness: 30
• Risk quality: 45
• Backtest evidence: 50
• Fundamentals trend: 55

Watch items

• HALO — Price vs 50-day EMA
• HALO — RSI (14)
• HALO — MACD line vs signal
• HALO — Second support level (stop)
• MRK — Price vs 50-day EMA
• MRK — RSI (14)
• MRK — Insider net open-market activity (provisional, Sept 30, 2026 filing)
• MRK — Quarterly dividend ex-date